Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

Disclosed herein is a pre-treatment and/or treatment formulation for transdermal delivery of a dermal pre-treatment agent and/or one or more dermal contouring agents through the skin of a subject, wherein the pre-treatment formulation comprises: a) a buffering agent comprising at least one carbonate salt, lysine, tris, a phosphate buffer and/or 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), or a combination thereof in an amount between about 0.05-60% w/w; and b) a pre-treatment penetrant portion in an amount between about 40 to 99.95% w/w, and wherein the treatment formulation comprises: a) one or more acylating agents in an amount between about 0.25-25% w/w; and b) a treatment penetrant portion in an amount between about 40 to 75% w/w and methods for transdermal delivery of the pretreatment and/or treatment formulation through the skin of a subject.

The present invention relates to the strain Phascolarctobacterium faecium DSM 32890 and to its use for the regulation of appetite and the treatment and/or prevention of overweight or the associated metabolic and immunological changes, specifically, hyperglycaemia, glucose intolerance, insulin resistance, dyslipidemia (hypertriglyceridemia, hypercholesterolemia), metabolic syndrome, diabetes and intestinal and/or peripheral tissue inflammation.

A compound of formula (I) R.sub.1-W.sub.m-X.sub.n-AA.sub.1-AA.sub.2-AA.sub.3-AA.sub.4-AA.sub.5-AA.sub.6-Y.sub.p-Z.sub.q-R.sub.2, a stereoisomer and/or cosmetically acceptable salt thereof, and a method of treatment using the compound are described. In the compound, AA.sub.1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA.sub.2 is Val, Ile, Leu or Ala; AA.sub.3 is Tyr, Phe, Trp, Lys, Arg or His; AA.sub.4 is Lys, Arg, His, Pro or Val; AA.sub.5 is Asn, Asp, Gln or no amino acid; AA.sub.6 is Thr, Ala, Ser or no amino acid. The compounds are useful for the treatment of the symptoms of skin aging and, in particular, for the treatment of skin wrinkles, the treatment of a sagging appearance of the skin, and/or the reduction of facial asymmetry.

A compound of formula (I) R.sub.1-W.sub.m-X.sub.n-AA.sub.1-AA.sub.2-AA.sub.3-AA.sub.4-AA.sub.5-AA.sub.6-Y.sub.p-Z.sub.q-R.sub.2, a stereoisomer and/or cosmetically acceptable salt thereof, and a method of treatment using the compound are described. In the compound, AA.sub.1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA.sub.2 is Val, Ile, Leu or Ala; AA.sub.3 is Tyr, Phe, Trp, Lys, Arg or His; AA.sub.4 is Lys, Arg, His, Pro or Val; AA.sub.5 is Asn, Asp, Gln or no amino acid; AA.sub.6 is Thr, Ala, Ser or no amino acid. The compounds are useful for the treatment of the symptoms of skin aging and, in particular, for the treatment of skin wrinkles, the treatment of a sagging appearance of the skin, and/or the reduction of facial asymmetry.

Sucrose esters such as sucrose laurate and sucrose dilaurate are notoriously difficult to emulsify in an oil-in-water emulsion and tend to destabilize these types of emulsions. It has now been found that combining a sucrose ester with certain hydrophobically modified aqueous rheology modifier and non-ionic stearic acid derivative emulsifiers can greatly improve emulsion stability.

A method of reducing the appearance of fine lines or wrinkles or increasing skin elasticity or skin firmness is disclosed. The method can include topically applying to the fine line or wrinkle or to sagging or loose skin an effective amount of a topical composition comprising a combination of vegetable amino acids from navy bean, Myrciaria dubia fruit extract, Peucedanum graveolens extract, and tetrahexyldecyl ascorbate. The combination can reduce the appearance of the fine line or wrinkle, increases skin elasticity, or increases skin firmness.